Charting the future through public-private partnerships
This article was originally published in SRA
This week the EU launched a multi-stakeholder project intended to help demonstrate the therapeutic and economic value of new medicines, while the UK government announced two collaborative initiatives to bring new drugs to market more effectively. All three developments are welcome evidence that the trend towards more public-private collaboration in drug development shows no sign of slowing.
You may also be interested in...
The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.